Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure
Public ClinicalTrials.gov record NCT00894387. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the 6 Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality When Initiated Early After Hospitalization for Acute Decompensated Heart Failure
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study evaluated the effect of early initiation of aliskiren therapy, compared to standard therapy, in the reduction of cardiovascular death and heart failure re-hospitalization events within 6 months, in congestive heart failure (CHF) patients hospitalized for an episode of acute decompensated heart failure.
Study identification
- NCT ID
- NCT00894387
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,639 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2009 (Type not available)
- Primary completion
- Aug 2012 (Actual)
- Completion
- Aug 2012 (Actual)
- Last update posted
- Nov 7, 2013
2009 – 2012
United States locations
- U.S. sites
- 37
- U.S. states
- 22
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Mobile | Alabama | 36608 | — |
| Novartis Investigative Site | Tucson | Arizona | 85723-0001 | — |
| Novartis Investigative Site | Los Angeles | California | 90073 | — |
| Novartis Investigative Site | San Diego | California | 92103 | — |
| Novartis Investigative Site | Sylmar | California | 91342 | — |
| Novartis Investigative Site | Torrance | California | 90502 | — |
| Novartis Investigative Site | Hartford | Connecticut | 06102-5037 | — |
| Novartis Investigative Site | Washington D.C. | District of Columbia | 20010-2975 | — |
| Novartis Investigative Site | Washington D.C. | District of Columbia | 20037 | — |
| Novartis Investigative Site | Jacksonville | Florida | 32207 | — |
| Novartis Investigative Site | Macon | Georgia | 31201 | — |
| Novartis Investigative Site | Oakbrook Terrace | Illinois | 60181 | — |
| Novartis Investigative Site | Iowa City | Iowa | 52245 | — |
| Novartis Investigative Site | Lafayette | Louisiana | 70501 | — |
| Novartis Investigative Site | Detroit | Michigan | 48202 | — |
| Novartis Investigative Site | Kalamazoo | Michigan | 49048 | — |
| Novartis Investigative Site | St Louis | Missouri | 63110 | — |
| Novartis Investigative Site | Cherry Hill | New Jersey | 08034 | — |
| Novartis Investigative Site | Newark | New Jersey | 07103-2714 | — |
| Novartis Investigative Site | Buffalo | New York | 14203 | — |
| Novartis Investigative Site | Buffalo | New York | 14215 | — |
| Novartis Investigative Site | Saratoga Springs | New York | 12866 | — |
| Novartis Investigative Site | The Bronx | New York | 10461 | — |
| Novartis Investigative Site | Chapel Hill | North Carolina | 27599-7075 | — |
| Novartis Investigative Site | Cincinnati | Ohio | 45219 | — |
| Novartis Investigative Site | Cincinnati | Ohio | 45267-0585 | — |
| Novartis Investigative Site | Cleveland | Ohio | 44109-1998 | — |
| Novartis Investigative Site | Philadelphia | Pennsylvania | 19102-1192 | — |
| Novartis Investigative Site | Philadelphia | Pennsylvania | 19140 | — |
| Novartis Investigative Site | Pittsburgh | Pennsylvania | 15212 | — |
| Novartis Investigative Site | Charleston | South Carolina | 29403 | — |
| Novartis Investigative Site | Rapid City | South Dakota | 57701 | — |
| Novartis Investigative Site | Springfield | Tennessee | 37172 | — |
| Novartis Investigative Site | Brownsville | Texas | 78520 | — |
| Novartis Investigative Site | Charlottesville | Virginia | 22908 | — |
| Novartis Investigative Site | Richmond | Virginia | 23249 | — |
| Novartis Investigative Site | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 271 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00894387, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 7, 2013 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00894387 live on ClinicalTrials.gov.